학술논문
ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria.
Document Type
Academic Journal
Author
Schwarz C; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.; Bauer D; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.; Dorn L; Internal Medicine 2, Gastroenterology and Hepatology and Rheumatology, Karl Landsteiner University of Health Sciences, University Hospital of St. Pölten, St. Pölten, Austria.; Jachs M; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Hartl L; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Chromy D; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Department of Dermatology, Medical University of Vienna, Vienna, Austria.; Weseslindtner L; Center for Virology, Medical University of Vienna, Vienna, Austria.; Pfisterer N; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Department of Internal Medicine IV, Klinik Landstraße, Vienna, Austria.; Hennlich B; Department of Internal Medicine IV, Klinik Landstraße, Vienna, Austria.; Stückler A; Department of Internal Medicine IV, Klinik Landstraße, Vienna, Austria.; Strassl R; Clinical Institute for Laboratory Medicine, Medical University of Vienna, Vienna, Austria.; Voill-Glaninger A; Central Laboratory and Blood Bank, Klinik Landstraße, Vienna, Austria.; Hübl W; Central Laboratory, Klinik Ottakring, Vienna, Austria.; Willheim M; Clinical Institute of Laboratory Medicine, University Clinic St. Pölten, St. Pölten, Austria.; Köhrer K; Institute of Medical-Chemical and Molecularbiological Laboratory Diagnostics with Blood Depot, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria.; Jansen-Skoupy S; Institute of Laboratory Diagnostics, Klinik Favoriten, Vienna, Austria.; Tomez S; Institute of Laboratory Medicine with Blood Depot, Klinik Donaustadt, Vienna, Austria.; Krugluger W; Institute of Laboratory Medicine with Blood Depot, Klinik Donaustadt, Vienna, Austria.; Institute of Laboratory Medicine and Blood Depot, Klinik Floridsdorf, Vienna, Austria.; Madl C; Department of Internal Medicine IV, Klinik Landstraße, Vienna, Austria.; Sigmund Freud University, Vienna, Austria.; Schwarz M; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.; Balcar L; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Semmler G; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Brinkmann L; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.; Burghart L; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria.; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.; Antonitsch L; Department of Internal Medicine, Gastroenterology and Hepatology, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria.; Weidinger G; Department of Internal Medicine, Gastroenterology and Hepatology, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria.; Riedl F; Internal Medicine 2, Gastroenterology and Hepatology and Rheumatology, Karl Landsteiner University of Health Sciences, University Hospital of St. Pölten, St. Pölten, Austria.; Laferl H; Department of Internal Medicine IV, Klinik Favoriten, Vienna, Austria.; Kurteva V; Department of Internal Medicine IV, Klinik Favoriten, Vienna, Austria.; Traugott M; Department of Internal Medicine IV, Klinik Favoriten, Vienna, Austria.; Hind J; Department of Internal Medicine IV, Klinik Favoriten, Vienna, Austria.; Wenisch C; Department of Internal Medicine IV, Klinik Favoriten, Vienna, Austria.; Aburaia A; Department of Internal Medicine and Gastroenterology, Klinik Floridsdorf, Vienna, Austria.; Sebesta C; Department of Internal Medicine and Gastroenterology, Klinik Floridsdorf, Vienna, Austria.; Department of Internal Medicine II, Klinik Donaustadt, Vienna, Austria.; Schmid D; Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH (AGES), Vienna, Austria.; Rothweiler S; Gilead Sciences, Vienna, Austria.; Remetic J; Gilead Sciences, Vienna, Austria.; Gschwantler M; Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.; Sigmund Freud University, Vienna, Austria.; Maieron A; Internal Medicine 2, Gastroenterology and Hepatology and Rheumatology, Karl Landsteiner University of Health Sciences, University Hospital of St. Pölten, St. Pölten, Austria.; Reiberger T; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.reiberger@meduniwien.ac.at.; Vienna HIV & Liver Study Group, Medical University of Vienna, Vienna, Austria. thomas.reiberger@meduniwien.ac.at.
Source
Publisher: Springer Country of Publication: Austria NLM ID: 21620870R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1613-7671 (Electronic) Linking ISSN: 00435325 NLM ISO Abbreviation: Wien Klin Wochenschr Subsets: MEDLINE
Subject
Language
English
Abstract
Background and Aims: Micro-elimination projects targeted to specific hepatitis C virus (HCV) risk populations have been successful. Systematic identification of persons with HCV viremia, regardless of risk group, based on already available laboratory records may represent an effective macroelimination approach to achieve global HCV elimination.
Methods: Persons with a last positive HCV-RNA PCR result between 2008-2020 in the reference virology laboratories in eastern Austria were identified. First, (i) we described their demographic characteristics, (ii) we systematically recalled persons to the respective centers and (iii) started antiviral treatment if HCV-RNA viremia was confirmed, and (iv) recorded sustained virologic response (SVR). This interim report includes the preliminary results from 8 participating centers.
Results: During the study period 22,682 persons underwent HCV-RNA PCR testing, 11,216 (49.4%) were positive at any point in time, and 6006 (26.5%) showed detectable HCV-RNA at the last PCR test, suggesting ongoing HCV viremia. At the time of this interim report, 2546/6006 HCV-RNA PCR(+) persons were evaluated: 443/2546 (17.4%) had died, 852/2546 (33.5%) had invalid contact data, and 547/2546 (21.5%) had achieved SVR between data retrieval and recall. Contact could be established in 236/704 (33.5%) of the remaining target population with 97/236 (41.1%) presenting at the clinic for treatment evaluation. Ultimately, 71/236 (30.1%) started antiviral treatment and SVR was documented in 47/71 (66.2%).
Conclusion: This ELIMINATE project based on systematic assessment of HCV-RNA PCR-records, identified 6006 persons with potential persisting HCV viremia. Invalid contact data and missed visits for treatment evaluation were the main barriers towards HCV elimination within this project. Importantly, many subjects with HCV viremia lost to follow-up were successfully linked to care and started antiviral treatment.
(© 2023. The Author(s).)
Methods: Persons with a last positive HCV-RNA PCR result between 2008-2020 in the reference virology laboratories in eastern Austria were identified. First, (i) we described their demographic characteristics, (ii) we systematically recalled persons to the respective centers and (iii) started antiviral treatment if HCV-RNA viremia was confirmed, and (iv) recorded sustained virologic response (SVR). This interim report includes the preliminary results from 8 participating centers.
Results: During the study period 22,682 persons underwent HCV-RNA PCR testing, 11,216 (49.4%) were positive at any point in time, and 6006 (26.5%) showed detectable HCV-RNA at the last PCR test, suggesting ongoing HCV viremia. At the time of this interim report, 2546/6006 HCV-RNA PCR(+) persons were evaluated: 443/2546 (17.4%) had died, 852/2546 (33.5%) had invalid contact data, and 547/2546 (21.5%) had achieved SVR between data retrieval and recall. Contact could be established in 236/704 (33.5%) of the remaining target population with 97/236 (41.1%) presenting at the clinic for treatment evaluation. Ultimately, 71/236 (30.1%) started antiviral treatment and SVR was documented in 47/71 (66.2%).
Conclusion: This ELIMINATE project based on systematic assessment of HCV-RNA PCR-records, identified 6006 persons with potential persisting HCV viremia. Invalid contact data and missed visits for treatment evaluation were the main barriers towards HCV elimination within this project. Importantly, many subjects with HCV viremia lost to follow-up were successfully linked to care and started antiviral treatment.
(© 2023. The Author(s).)